bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company’s product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; LYFGENIA (lovotibeglogene autotemcel) for the treatment of sickle cell disease (SCD) and a history of vaso-occlusive events; and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.
Gene Therapy Pionee | Explore bluebird bio's innovative treatments for severe genetic diseases, including its lead product Lyfgenia for sickle cell disease |
Financial Tightrope | Delve into bluebird's financial challenges, with a limited runway extending into Q1 2025 and efforts to reach cash flow break-even by H2 2025 |
Market Potential | Analyst price targets range from $2 to $40, reflecting diverse views on bluebird's growth prospects in the expanding gene therapy market |
Launch Execution | Learn about bluebird's progress in patient starts across treatments and the critical importance of successful product launches for future success |
Metrics to compare | BLUE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBLUEPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.2x | −2.1x | −0.5x | |
PEG Ratio | −0.01 | −0.01 | 0.00 | |
Price/Book | −1.5x | 1.2x | 2.6x | |
Price / LTM Sales | 0.6x | 17.6x | 2.9x | |
Upside (Analyst Target) | 61.3% | 557.4% | 51.4% | |
Fair Value Upside | Unlock | 7.6% | 9.5% | Unlock |